StevenPatrickMarsoMD

PubMed

• 11 citations
  Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEV...
  Klara R. Klein, Edward Franek, Steven P. Marso, Thomas R. Pieber, Richard E. Pratley, Amoolya Gowda, Kajsa Kvist, John B. Buse> ;BMJ Open Diabetes Research & Care. 2021 Nov 1
• 49 citations
  Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, c...
  Ian J. Neeland, Steven P. Marso, Colby Ayers, Bienka Lewis, Robert Oslica, Wynona Francis, Susan G. Rodder, Ambarish Pandey, Parag H. Joshi> ;The Lancet. Diabetes & Endocrinology. 2021 Sep 1
• The Self Work of Becoming a CTO Operator.
  Steven P. Marso> ;Interventional Cardiology Clinics. 2021 Jan 1
• 7 citations
  Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE.
  Simon Heller, Ildiko Lingvay, Steven P. Marso, Athena Philis-Tsimikas, Thomas R. Pieber, Neil R Poulter, Richard E. Pratley, Elise Hachmann-Nielsen, Kajsa Kvist, Marti...> ;Diabetes, Obesity & Metabolism. 2020 Dec 1
• 70 citations
  Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised contr...
  Johannes F.E. Mann, Thomas Kruse Hansen, Thomas Idorn, Lawrence A. Leiter, Steven P. Marso, Peter Rossing, Jochen Seufert, Sayeh Tadayon, Tina Vilsbøll> ;The Lancet. Diabetes & Endocrinology. 2020 Nov 1
• 23 citations
  Management of Percutaneous Coronary Intervention Complications: Algorithms from the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications Conference
  Jacob A. Doll, Ravi S. Hira, Kathleen E. Kearney, David E. Kandzari, Robert F. Riley, Steven P. Marso, J A Grantham, Craig Thompson, James M. McCabe, Dimitrios Karmpal...> ;Circulation. Cardiovascular Interventions. 2020 Jun 1
• 6 citations
  Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
  Simon Heller, Ildiko Lingvay, Steven P. Marso, Athena Philis-Tsimikas, Thomas R. Pieber, Neil R Poulter, Richard E. Pratley, Elise Hachmann-Nielsen, Kajsa Kvist, Marti...> ;Diabetes, Obesity & Metabolism. 2020 Apr 6
• 49 citations
  Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
  Steven P. Marso, Florian M.M. Baeres, Stephen C. Bain, Bryan Goldman, Mansoor Husain, Michael A. Nauck, Neil R Poulter, Richard E. Pratley, Anne B. Thomsen, John B. Bu...> ;Journal of the American College of Cardiology. 2020 Mar 17
• 8 citations
  Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
  Richard F Pollock, William J. Valentine, Steven P. Marso, Andreas Andersen, Jens Gundgaard, Nino Hallén, Deniz Tutkunkardas, Elizabeth A. Magnuson, John B. Buse> ;Applied Health Economics and Health Policy. 2019 Oct 1
• 383 citations
  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
  Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pe...> ;The New England Journal of Medicine. 2019 Aug 29
• 14 citations
  Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results ...
  Richard E. Pratley, Scott S. Emerson, Edward Franek, Matthew P. Gilbert, Steven P. Marso, Darren K. McGuire, Thomas R. Pieber, Bernard Zinman, Charlotte T. Hansen, Mel...> ;Diabetes, Obesity & Metabolism. 2019 Jul 1
• 249 citations
  Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock Initiative
  Mir B Basir, Navin K. Kapur, Kirit Patel, Murad A Salam, Theodore Schreiber, Amir Kaki, Ivan Hanson, Steve Almany, Steve Timmis, Simon R. Dixon, Brian Kolski, Josh Tod...> ;Catheterization and Cardiovascular Interventions. 2019 Jun 1
• 24 citations
  Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina.
  , , , , , , , , , , , , , , , , , > ;Circulation. Cardiovascular Interventions. 2019 Mar 1
• 70 citations
  Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
  Subodh Verma, Neil R Poulter, Deepak L. Bhatt, Stephen C. Bain, John B. Buse, Lawrence A. Leiter, Michael A. Nauck, Richard E. Pratley, Bernard Zinman, David D. Ørsted...> ;Circulation. 2018 Dec 18
• Treating Leave Behind Lesions.
  Steven P. Marso> ;Circulation. Cardiovascular Interventions. 2018 Oct 1
• 22 citations
  Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use
  Subodh Verma, Lawrence A. Leiter, C. David Mazer, Stephen C. Bain, John B. Buse, S. Marso, Michael A. Nauck, Bernard Zinman, Heidrun Bosch-Traberg, Søren Rasmussen, Ma...> ;Circulation. 2018 Oct 9
• 3 citations
  Relationship between left main coronary artery plaque burden and nonleft main coronary atherosclerosis: results from the PROSPECT study.
  Takehisa Shimizu, Gary S. Mintz, Bernard De Bruyne, Naim Farhat, Shinji Inaba, Yang Cao, Steven P. Marso, Patrick W. Serruys, Gregg W. Stone, Akiko Maehara> ;Coronary Artery Disease. 2018 Aug 1
• 68 citations
  Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
  Bernard Zinman, Steven P. Marso, Erik Christiansen, Salvatore Calanna, Søren Rasmussen, John B. Buse> ;Diabetes Care. 2018 Aug 1
• 17 citations
  Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
  Michael A. Nauck, Karen Tornøe, Søren Rasmussen, Marianne Bach Treppendahl, Steven P. Marso> ;Diabetes & Vascular Disease Research. 2018 Jun 27
• 53 citations
  Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
  Subodh Verma, Deepak L. Bhatt, Stephen C. Bain, John B. Buse, Johannes F.E. Mann, Steven P. Marso, Michael A. Nauck, Neil Poulter, Richard E. Pratley, Bernard Zinman, ...> ;Circulation. 2018 May 15
• 37 citations
  Impact of subintimal plaque modification procedures on health status after unsuccessful chronic total occlusion angioplasty.
  , , , , , , , , , , , , , , , , , > ;Catheterization and Cardiovascular Interventions. 2018 May 1
• 10 citations
  DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
  Richard F Pollock, William J. Valentine, Steven P. Marso, Jens Gundgaard, Nino Hallén, Lars Hansen, Deniz Tutkunkardas, John B. Buse> ;Diabetes Therapy. 2018 Apr 30
• 13 citations
  Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).
  Steven P. Marso, Michael A. Nauck, Tea Monk Fries, Søren Rasmussen, Marianne Bach Treppendahl, John B. Buse> ;The American Journal of Cardiology. 2018 Jun 15
• 55 citations
  Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials
  Melanie J. Davies, Louis J. Aronne, Ian D. Caterson, Anne B. Thomsen, P. B. Jacobsen, Steven P. Marso> ;Diabetes, Obesity & Metabolism. 2018 Mar 1
• 7 citations
  Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
  Steven P. Marso, Elise Hardy, Jenny Han, Hui Wang, Robert J. Chilton> ;Diabetes Therapy. 2018 Feb 3
• Join now to see all

Journal Articles

• Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience  
  Steven P Marso, John B Buse, Diabetes Care